A Secondary Analysis of Imatinib Adherence Among Patients with Chronic Myeloid Leukemia

Persistent Link:
http://hdl.handle.net/10150/156890
Title:
A Secondary Analysis of Imatinib Adherence Among Patients with Chronic Myeloid Leukemia
Author:
Beaver, Melissa A.
Issue Date:
Dec-2010
Publisher:
The University of Arizona.
Rights:
Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
Abstract:
Background: Two recent studies have identified a strong association between treatment adherence and treatment response in patients with chronic myeloid leukemia (CML) treated with imatinib; and suggested a possible 7-10% tolerance margin for nonadherence before impaired treatment response is likely to occur. Objective: To determine at what percentage of dosing adherence of imatinib impaired treatment response (suboptimal response of incomplete cytogenetic response is likely to occur; and, conversely, at what percent of dosing adherence positive treatment response is likely to ensue CML patients.
Type:
text; Electronic Thesis
Degree Name:
B.S.
Degree Level:
bachelors
Degree Program:
Honors College; Nursing
Degree Grantor:
University of Arizona

Full metadata record

DC FieldValue Language
dc.language.isoenen_US
dc.titleA Secondary Analysis of Imatinib Adherence Among Patients with Chronic Myeloid Leukemiaen_US
dc.creatorBeaver, Melissa A.en_US
dc.contributor.authorBeaver, Melissa A.en_US
dc.date.issued2010-12-
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en_US
dc.description.abstractBackground: Two recent studies have identified a strong association between treatment adherence and treatment response in patients with chronic myeloid leukemia (CML) treated with imatinib; and suggested a possible 7-10% tolerance margin for nonadherence before impaired treatment response is likely to occur. Objective: To determine at what percentage of dosing adherence of imatinib impaired treatment response (suboptimal response of incomplete cytogenetic response is likely to occur; and, conversely, at what percent of dosing adherence positive treatment response is likely to ensue CML patients.en_US
dc.typetexten_US
dc.typeElectronic Thesisen_US
thesis.degree.nameB.S.en_US
thesis.degree.levelbachelorsen_US
thesis.degree.disciplineHonors Collegeen_US
thesis.degree.disciplineNursingen_US
thesis.degree.grantorUniversity of Arizonaen_US
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.